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TIRE measure ofsuccess which has attended the use ofthenitrogen mustards in
the palhation of certain forms of human mahgna'nt disease, notably those of
reticulo-endothelial origin, has led to a wider search among compounds of the
same and of analogous chemical type for altemative and more efficient thera-
peutic agents.
The water-soluble trisethyleneimino-s-triazine (Fig. 1) has been investigated
in this connection independently on both sides of the Atlantic. In England its
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FIG. I.-Trisethyleneimino-s-triazine.
cytotoxic andtumour-inhibitoryactivity, were first demonstrated in the Research
Laboratories of Imperial Chemical Industries Ltd. (Rose, Hendry and Walpole,
1950), where it is known as
" 9500."
The compound has been tested for its effect upon a wide variety ofbiological
materials (Rose, Hendry and Walpole, 1950; Lewis and Crossley, 1950; Bur-
chenal, Crossley, Stock and Rhoads, 1950; Burchenal, Johnston, Cremer,
Webber and Stock, 1950). In our own laboratories it has been tested on cells
grown invitro, and upon leukaemia and tumours in rodents.
Effect,3 on Animal'Tiss-ues and Tumours.
Effect on cell8in vitro.
Chick fibroblasts which had been growing for 24 hours as hanging drop pre-
parations were treatedby the addition to the medium of a drop of 9500 inTyrode
solution, in concentrations ranging from 12-5 mg./litre to 62-5 mg./litre. At the
end of 80 minutes the cultures were fixed and stained an'd mitotic counts were
done. As a control similar sets of cultures were treated with Tyrode solution.TRISETHYLENEIMINO-S-TRIAZINE IN HUMAN MALIGNANT DISEASE 29
The reduction in mitosis is shown inFig. 2, where it wiR be seen that the
addition to the medium of the drug in a concentration of 60 mg./litre reduces
mitosis to less than one half. With thetechnique used it is not possible to state
the final concentration in the medium which would of course be less. This
reduction in mitosis is quantitatively similar to that found 80 minutes after the
application of 30 r X-rays.
The effects produced also demonstrate the direct action of the drug on cells.
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YiG. 2.-Reduction in mitosis in fibroblasts, fixed 80 minutes after the application of various concentrations of 9500.
-lfouse leukaemia.
Mice ofthe Afb straininjectedintraperitoneally with leukaemic cens of mono-
cytic type from a spontaneously occurring case, were given the drug intraperi- toneally in 5 ydoses, twicedaily,starting 24 hours after theinjection, for aperiod of 5 days; in one experiment alengthening ofsurvival time over several months
was obtained. Re-treatment, at the same dose levels, lengthened survival time
still further. In a second experiment, using leukaemic cells from a different
mouse with lymphocytic leukaemia, the mean su-rvival time was lengthened by only a few days.30 EDITH PATERSON AND J. BOLAND
Rat lympho8arcoma.
Rats of the American Wistar strain were injected with a rat lymphosarcoma
subcutaneously. After 20 dayseight often untreated animals had beendisposed
of on account of the size of the tumours. Two groups, each of ten rats, were
given 9500 intraperitoneaRy in doses of 0-5 mg./kg. spread over 5 days and the
effects assessed after 20 days. In one group treatment was started 6 days after
the in.ection, when the tumour was estabhshed ; in this group four rats had been
disposed of. In the second group in which treatment was started 24 hours after
the injection of the tumour, only three rats had been disposed of, and in five no
tumour appeared.
Mou8e mammary adenocarcinoma.
Grafts of mammary carcinoma from the C3H and A strain of mice were
established in pure-bred mice of the same strains. The drug was given intra-
peritoneaRy in doses of 5 y twice daily over a 5-day period. There was no diffe-
rence between treated and untreated mice in the time ofdisposal.
AR experimental animals have shown a temporary loss ofweight after being
given the drug.
Effed,8 on Human Malignant Di8ea8e.
This report, which is prehminary in nature, describes the testing of the com-
pound in 17 patients suffering from leukaemia, polycvthaemia vera, lymphade-
noma, multiplemyeloma and three types ofcarcinoma.
Cases were chosen becausethey were unfavourable or too advanced for other
forms of treatment. This choice of the least favourable cases -makes it harder
to comparetheeffects ofthedrugwitheffectsobtainedwithotherformsoftherapy.
it is, however, of value to compare in any individual patient the effects of the
drug against those of any other type ofappropriate treatment given either prior
or subsequent to 9500. This we have done where possible.
The drug was given intravenously in doses ranging from 0-09 mg./kg. to 0
mg./kg. the total dose usuaRy being spread over 3 days. On the basis of our
experience we feel that a total dose between 0-15 and 0-18 mg./kg. probably
represents a working range within which toxic effects on the bone marrow are not
serious.
Side effects were slight ; half the patients had anorexia or nausea, generaRy
very shght. The only patient who vomited did so after a dose of 0-22 mg./kg.,
the highest dose we have given. The gastric side effects are therefore much
less than those accompanying treatment with the nitrogen mustards. Further-
more, no local effects occur at the site of the injection; in this respect 9500 has
the advantage over the nitrogen mustards.
Leukaemia andpolycythaemia.
Nine patients in all were treated; of these one is excluded from analysis as
death occurred from pneumonia shortly after completion of treatment, and
following an anaesthetic for a coincidental prostatic obstruction. Of the six
leukaemia cases reported, four were either terminal chronic cases or else acute
in type. Transfusions were necessary in several of the patients before and afterTRISETHYLENEIMINO-S-TRIAZINE IN HUMAN MALIGNANT DISEASE 31
treatment and this necessity has to some extent confused the assessment of the
value, ofthedrug. Some ofthe data on these cases are given in Table I.
TABLE I.
I F. 5o Chronic myeloid
leukaemia
II F. 42 Ditto
III F. 63 Myeloblastic leukaemia
IV F. 61 119 911)
v F. 62 Subacute lymphoid
leukaemia
VI . M. 3 Acute lymphoid
leukaemia
vii . F. 74 Polycythaemia and
leukaemia
VIII F. 66 Polycythaemia
Total dose.
(mg./kg. over 3 days).
0- 22
0.15
0-15
0-22
Ist Course 0-17
2nd 0-13
3rd 0-18
Ist Course 0
- 1
(I day)
2nd Course 0
- 2
(2 days)
0.15
lst Course 0-09
2nd ,, 0-12
Number. Sex. Age. Diagnosis. Side effects.
Nausea and vomiting.
Nausea
Nil
Nausea
Nil
91,
9 9
Nausea
Case I. Chronic myeloid leukaemia.-This patient was in fair general con-
dition and had previously been treated successfully with urethane, the rernission
so obtainedlastingfor oneyear. Considerableimprovementinwen-beingfollowed
treatment with 9500 ; her weight which was 45 kg. before treatment increased
to 54 kg. during the 6 months she has been under observation. The splenic
enlargement decreased within 2 weeks and this decrease, while not dramatic,
was maintained. The dose used in this case resulted in atemporaryfan in haemo-
globin and a fall in the white blood count to 1000 per c.mm., at which time she
was given a simple blood transfusion. The haemoglobin percentage recovered
and 6 months later was above pre-treatment level. The percentage ofprimitive cells fell after treatment, but had reached theoriginal level at 6 months (Fig. 3).
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FIG. 3.-Case I: Chronic myeloid leukaemia. Effect of 9500 on peripheral blood count.32 EDITH PATERSON AND J. BOLAND
In this case the improvenient obtained was about the same as would be
expected after a non-repetitive course of treatment with X-rays or urethane.
Case IL Chronic myeloid leukaemia.-This patient had previously obtained
a satisfactory remission of 14 months' duration with a single course of splenic
irradiation. At the end of this remission she was suffering from lassitude and
abdominal discomfort, and arising white blood,count. Following treatment with
9500 her well-being improved; her white cell count fell and the haemoglobin,
which was 86 per cent, rose slightlv. Primitive cells fell from 26 per cent to 14
per cent within 4 davs. The siibsequent historyofthis patient was complicated,
2 months -after treatment, by,'hepatogenous jaundice with leukopenia. Four
months after treatment the'haemoglobin began to fall and the white cell count
commenced to rise, and sore throat appeared, primitive cells rising above the
pre-treatment level. She was re-treated a month later with 9500, no beneficial
effects being observed in the week that elapsed between treatment and death.
Post-mortem examination showed a massive leukaemic infiltration of liver,
kidneys and spleen. The bone-marrow from femur and sternum appeared active.
Multiple capillary haemorrhages were present in the myocardium and brain. It
is difficult to assess the effect of treatment in this case owing to the complicating
factors. The i-emission, however, was not as satisfactory as that previously
obtained with X-rays.
Case III. Myeloblastic leukaemia ofNaegeli type.-This was a terminal case
which had been treated previously only with transfusions. Within 7 days after
treatment the haemoglobin rose and the white cell count fell from 145,000 to
within normal limits. Primitive cells fell from a pre-treatment level of 76 per
cent to 37 per cent andthemyeloblasts andpremyelocytesdisappearedcompletely.
However, this remission, although dramatic, was short. Two months later the
patient was as ill as before treatment.
Case IV. Myeloblastic leukaemia.-This rather acute case showed a genuine
improvement, although of short duratio'n, following treatment. Prior to adrnis-
sion she had been transfused and it was necessary to repeat transfasions for the
very low red cell count. Animprovement in theleukaemic condition wasprompt.
Five days after the first treatment the total white cell count was within normal
limits and immature cells had been reduced from 40 per cent to'6 per cent ofthe
total. Improvement was not maintained and 3 months after treatment the
immature cells had risen to pre-treatment level. At no time was the spleen
palpable in this patient. The m'ain findings are shown- in the graph (Fig. 4),
which demonstrates the immediate reduction in total white cells and the almost
complete absence ofcirculating immature cells for somedaysfollowing treatment.
lncidentally it will be noted that transfusions did not reduce the percentage of
immature cells.
Case V. Subacute lymphoid leukaemia.-This patient had been treated with
splenic irradiation the response to which had lasted. less than 2 months.
At the time oftreatment with 9500 hergeneral condition was extremely poor.
The haemoglobin was 18 per cent and a high percentage of her white cells were
immature. Transfusions were done repeatedly during treatment, but without
any lasting effect on the red cell count. However, after each treatment with
9500 a dramatic fall in the white cell count occurred; the immature cells, after
an initial rise, fell markedly. The size of the spleen increased immediately after
each treatment, then decreased in size. In this case the effects on total whiteTRISETHYLENEIMINO-S-TRIAZINE IN HUMAN MALIGNANT DISEASE 33
ceUs and onprimitive cells seemed to be a result ofthedrug. Thepatient died 4
months after treatment with 9500. There was no post mortem examination.
Case VI. Acute lyinphoid leukaemia.-This child presented with lympho-
sarcomatous tumours. The marrow was infiltrated with lymphocytes and these
appeared in the blood stream in large numbers. There was, no evidence that the
drug affected the course ofthe disease.
'Case VII. Polycythaemia v6ra.-This case ofpolycythaemia with leukaemia,
had been treated for 3 years with X-ray therapy ; over the first 21 years splenic
irradiation had been used, but as the remissions obtained became progressively
slower and shghter in degree, whole-body irradiation had been instituted (175 r
over 23 days). The resulting remission became apparent 2 months after treat-
ment but was reasonablv satisfactory and lasted for about 4 months. She was
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FIG. 4.-Case IV: Myeloblastic leukaemia. Effect of 9500 onperipheral blood count.
then given 9500. A good remission was noted 20 davs after treatment, which
compared well with her first and best remission foHowing splenic irradiation. The patient felt better within a few days. A reduction in red cells and haemo- globin to normal levels was accompanied with a similarreduction in the leukaemic blood count. The platelet count remained high, but a difference in size was observed in that after treatment the platelets became larger'. The spleen showed an immediate reduction in size.
Case VIII. Polycythaemia vera.-This patient had previously been treated with radio-active.phosphorus, and as a consequence the red cell count and haemo- globin had been reduced to within normal liniits. Very httle effect was noted
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on the enlarged spleeti. The remission as far as the blood count was concerned
lasted one month. After 9500 a similar reduction in red cells and haemoglobin
occurred. This las'ted 4 months, after which the symptoms recurred. The
patient is feeble-minded and it is therefore not possible to assess the subjective
improvement accurately.
In both polycythaemia cases the clinical effects were as good, or better, as
had been obtained by their previous treatments. In neither patient, however,
was a reduction in the platelets obtained.
Lymphaden-oma.
In Table II are shown the doses and some of the constitutional and haemato-
logical results- of the drug in Hodgkin's disease. 'The effects can be compared
very exactly with those of the nitrogen mustards. Both drugs reduce the red
cell count and haemoglobin and a temporary leukopenia generaRy occurs.
TABLIF, 11.
Hb.
I -1
W.B.C.
Time
Time of Lowest after
recovery. count. treat-
ment
(days).
Unassessed ; -No fall -
Total dose
Diagnosis. (mg./kg.
over 3 days).
Side Fall in
effects. Hb
M
Nil 12
Number. Sex. Age.
IX . M. . 61 . Generalized .
lymphadenoma
0- 137 . I .-.-
subsequent
HN2
. Complete at . 2100 .
2 months
. 2100 .
x . M. . 67 .
XI . M. . 40 .
Ditto 0-195 - Slight
. 4
nausea
0-18 Nil . None
(trans-
fusion)
0.15 . A-norexia. 16
14
13
37
3
21
10
13
8
- - --0--
-----C5
2 months
12 . Not recovered.
5 months
. Beginning . XII . F. . 65 Multiple
myeloma
800 .
3300 .
1100 .
XIII 'M. 48 bitto lst Course
0.10
2nd Course
0-175
XIEV M. 29 Seminoma 0-18
xv M. 66 Melanoma lst- Course
0-2
2nd Course
0-2
(14 days)
XVI M. 64 Carcinoma 0-12
alveolus (7 days)
Nausea .
and
malaise
Nil
12 . Beginning
. 3600 .
2 months
8 . Not recovered. 3200 .
2 months
. 2300 .
Nil 20
(bleed-
ingfrom
tumour)
.No fall.
Ca8e IX. Generalized lymphadenoma (section proved).-This patient was
given a rather low dose of 9500. Nevertheless the enlarged nodes decreased
very temporarily and the skin itching from which he suffered disappeared for
-about a week. The good effects were so transient that after an interval of 3.
weeks he was given nitrogen mustard (0-4 mg./kg.). A Ion er lasting effect was
,obtained on his nodes and on his skin irritation. It is possible that a more com-
parable effect would have been obtained with 9500 at a somewhat-higher dose.zs
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Ca8e X. Generalized lymphadenoma.-The main symptoms in this case were
severe skin itching and the presence of a mediastinal mass. A drill-biopsy of
the mass did notyield conclusiveproofoflymphadenoma, which was nevertheless
probable on clinical grounds. Following treatment the itching was reduced and
the skin, which was dry and iethyotic, became more normal in texture. Some
xeduction in the mediastinal mass occurred (Fig. 5). The relief of symptoms
lasted less than 3 months. This patient showed an interesting initial rise in the
polymorphonuclear count at 4 days, prior to the onset ofleukopenia. Lympho-
.cytes and eosinophils were markedly reduced; both recovered to pre-treatment
levels at 2 months. The effects in this case were aboutequivalent to those which
would be expected with nitrogen mustard.
Ca8e XI. Generalized lymphadenoma.-This patient, a biopsy-proved case,
had previously been treated with local deep X-ray therapy and later on two
occasions, with nitrogen mustard. On both these occasions improvement in
well-being occurred and some reduction tookplace in the size ofhisenlargedliver,
-the improvement after the second course of nitrogen mustard being much less.
On admission for treatment with 9500, the liver was enlarged and oedema ofthe
legs was present. A transfusionpreceded treatment, and this obscured the effect
of the drug on the red cell count and haemoglobin. A short remission was
obtained: the liver became smaller, the oedema disappeared and the patient
.felt better. Thetotaleffect obtained wascomparable withthatfollowingnitrogen
mustard'with this difference, that nausea and vomiting had accompanied the
previous treatments.
Multi le myeloma.
Ca8e XII.-This section-proved case with positive Bence-Jones test showed
no subjective or objective improvement foUowing treatment. X-ray therapy
given coincidentaUy to one of her lesioiis reduced the local pain and swelling.
Ca8e XIII.-This patient, also a section-proved case, but with a negative
Bence-Jones test, showed considerable symptomatic improvement in that the
mobility of his shoulder was increased and pain was lessened. There was no
radiographic evidence of restoration ofthe affectedscapula. However, 5 months
later the radiographs did not show any advance ofthe lesion.
MiWellaneou8 carcinomata.
Ca868 XIV, XV and XVI.-These cases represented various advanced stages
of epithelial malignant growths. None of them responded to the drug. Case
XV was later given a second course of treatment simultaneously with X-ray
therapy, bothagentsbeinggiven asweekly treatments forgrowth-restraint. The
drug wasalwaysinjected before the radiation wasgiven. The amount ofgrowth-
restraint so obtained wasshght and no more than would have beenexpected from
the radiation alone.
EFFECT ON NON-LEUKAEMIC BLOOD.
The effect on the non-leukaemic blood count is superficially similar to that
which follows other cytotoxic agents, e.g. the nitrogen mustards or total body
irradiation when these agents are used at dose levels in the clinical range. Ure-
thane on the other hand, affects the normal blood count less.36 EDITH PATERSON AND J. BOLAND
The red cell count andhaemoglobinpercentage fall in most cases and recovery
to pre-treatment levels may take several months. A leukopenia is generaRy
seen, especiaRy at higher dose levels. This is due to a fall in both granular and
lymphocyte series.
The fafl in the granular cells may be preceded by a transitory rise over 3 to
4 days, not seen unless blood counts are repeated soon after treatment. The
minimum count occurs between 2 and 3 weeks foHowing treatment; thereafter'
recovery begins (Fig. 6).
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FIG. 6.-Case X: Lymphadenoma. Effect of 9500 on peripheral blood count in a
non-leukaemic case.
No initial rise has been seen in thelymphocyte count, which reaches thelowest
level 1 to 7 days after the end of treatment. Complete recovery is slow and
would seem to take about 2 months. The response ofother types of'cens, large
mononuclear and eosinophil granulocytes is irregular. Flatelets were unaffected
in all cases except one, in which a temporary diminution occurred.
A more exact comparison of the effects of 9500 and other cytotoxic agents
would require a much larger series of cases.
DISCUSSION AND SUMMARY.
T6 value of a new chemotherapy agent against malignant disease depends on
its superiority to radiation treatment or to those chemicals which have alreadyTRISETHYLENEIMINO-S-TRIAZiNE IN HUMAN MALIGNANT DISEASE 37
been evaluated clinically. It cannot be said on the evidence presented that tris-
,ethyleneimino-s-triazine is this superior agent.
In its fairly immediate effects on cases ofleukaernia, ofpolycythaemia and of
Hodgkin's disease, and in one case ofmyelomatosis, 9500 would seem aboutequal
to the estabhshed methods of treatment. The long-term effects have not yet
been studied.
The effects on the normal blood count resemble closely those obtained with
the nitrogen mustards, or with irradiation when given in certain ways, in that
the full effect on the white cell count is not seen until 2 to 3 weeks have elapsed.
Individual variation in the response to the drug occurs although probably to no
greater extent than obtains with other methods of treatment. For these two
reasons we have waited for several weeks before instituting a second course of
treatment in any patient.
An extended clinical trial of 9500 would, however, seem to be justified on
several grounds: First because it may be found effective in diseases other than
those quoted; even among the cases described there would seem to be aplace for
it in the treatment of polycythaemia. Secondly, it could be regarded as a
pleasanter alternative to nitrogen mustard, since, unlike nitrogen mustard, 9500
does notproducegastric effects and there is no fear oflocal thrombosis. Thirdly,
thedrugis active ifgivenby mouth ; we have so far not tried its clinicaleffective-
ness by this method, since, animal experiments have demonstrated that by this
route thehaematological response was lesspredictable.
There is one disadvantage to an easily given drug of such potency. It is
possible that it might be used without the constant supervision and check of
blood counts which is necessary. As with all cytotoxic agents, its use should be
contemplated only by those with facilities foradequate laboratory examinations.
The tissue culture work has been carried out by M. V. Thompson, the many
blood counts by the Haematological Department of the Hospital, and the work
on rat lymphosarcoma by Dr. H, Jackson. To all of these the authors
acknowledge their indebtedness.
The authors also wish to record the assistance of a grant from the Lady Tata
Memorial Trust.
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